AstraZeneca (LSE:AZN) was the standout performer on a London session that otherwise lacked direction. The shares rose 6.96% on Friday, the stock's best day in a year, after the drugmaker reported third-quarter results that beat expectations and announced a restructuring and savings programme worth roughly $1.5bn.

The headline numbers explain the enthusiasm. Pretax profit rose 22% in the quarter, while Revenue grew by between 6.7% and 7%, depending on the measure reported. Management also reaffirmed its full-year guidance, which gave investors reassurance that the good quarter was not a one-off and that the company still expects to deliver on its targets for the rest of the year. The cost-cutting plan, put at about $1.5bn, added a second reason to like the update: it signalled that the company intends to run its operations more efficiently while profit is already growing at a double-digit rate.

AstraZeneca (LSE:AZN) is one of the largest companies on the London market. It discovers, develops and sells prescription medicines, with a broad portfolio that spans cancer treatments, heart and metabolic conditions, respiratory care and rare diseases. Because it is so heavily weighted in the FTSE 100, a move of this size in a single stock carries real weight for the index, and it helps explain why the Blue-Chip benchmark held up on a day when much of the rest of the market struggled.

That backdrop was difficult. The FTSE 100 closed up just 7.71 points, or 0.07%, at 10,729.78, after drifting in and out of positive territory and finishing well off its intraday highs. It was the last session of October, and the index rose just over 1% across the month, its first monthly gain in three months, and about 0.37% on the week. Beneath the surface, the picture was more fragile. The FTSE 250 fell 0.9% to 24,453.36 and the AIM All-Share lost 1.4%, a sign that domestically focused mid-cap and smaller companies were under more pressure than the large defensives that dominate the headline index.

The pressure came largely from the United States. Weak results from Intel and Amazon, released after Thursday's close, revived doubts that heavy spending on artificial intelligence will pay off, and the Nasdaq Composite was down about 2.7% by the London close. Alphabet had already fallen 12% on Thursday over the same worries. In London, technology-exposed names such as Computacenter (LSE:CCC), Polar Capital Technology (LSE:PCT) and Scottish Mortgage (LSE:SMT) all declined. Miners fell as gold dropped about 2.8% to roughly $3,898 an ounce and copper slipped. NatWest (LSE:NWG) lost about 8.8% after disappointing net interest Margin guidance, dragging on Lloyds (LSE:LLOY) and Barclays (LSE:BARC).

Against that, defensive stocks did the heavy lifting. Consumer staples gained broadly, with Diageo (LSE:DGE), Coca-Cola Europacific Partners (LSE:CCEP), Unilever (LSE:ULVR), British American Tobacco (LSE:BATS), Reckitt (LSE:RKT), Sainsbury (LSE:SBRY) and Tesco (LSE:TSCO) all higher, and BT (LSE:BT.A) rose 6.7% on a press report that Virgin Media O2 is nearing a deal to use Openreach. Pharmaceuticals fitted the same pattern. GSK (LSE:GSK) rose 2.26% on the day, with no company-specific news identified, simply moving in the slipstream of its larger rival's results-driven surge.

AstraZeneca's rise therefore had two parts. The first was company-specific: a quarterly beat, reaffirmed full-year guidance and a clear plan to cut costs. The second was the market setting, in which investors were looking for businesses with steady Earnings and little direct exposure to the artificial intelligence trade that was unravelling across the Atlantic. A drugmaker reporting growing profit and revenue ticked both boxes at once.

Elsewhere in the economy, UK house price data showed the slowest October growth since 2024, sterling briefly topped 1.20 euros for the first time since April 2025, and Brent Crude rose to about $117.61 a barrel. None of these bore directly on the drugmaker's results.